291-OR: A Noninvasive Index for Significant Liver Fibrosis and Stratifying Risk of Cirrhosis in Patients with Type 2 Diabetes Mellitus in Primary Care

Introduction 0.01) risk for cirrhosis (Figure C). Conclusions: The non-invasive ADD index can be applied to screen significant fibrosis and cirrhosis in patients with T2DM in primary care, and promoting those in high-risk group to further consult a hepatologist in secondary care. Disclosure X. Qi: None. D. You: None. J. Shen: None. C. Liu: None. Y. Chen: None. M. Zheng: None. X. Zhou: None. M. Huang: None. X. Liang: None. T. Deng: None. C. Sun: None. X. Liang: None. H. Wan: None. Y. Wang: None. Y. Zhu: None. F. Lv: None. T.T. Zhou: None. S. Liu: None. X. Wang: None. X. Liu: None. R. He: None. J. Li: None. Y. Zhao: None. V.W. Wong: Consultant; AbbVie Inc., Boehringer-Ingelheim, Echosens, Gilead Sciences, Inc. Research Support; Gilead Sciences, Inc. Consultant; Intercept Pharmaceuticals, Inc., Inventiva Pharma, Novo Nordisk, Pfizer Inc., Sagimet Biosciences.